Invida specialty care provides healthcare professionals with clinically proven products in the management and treatment of medical conditions by specialists.  The current range of products support specialist practice in the field of neurology and oncology.

The Invida neurology portfolio aims to provide neurologists with clinically proven products in the treatment of Myasthenia Gravis (MG). MG is a neuromuscular disease characterised by weakness of the voluntary muscles. The first line treatment involves the use of acetylcholinesterase inhibitors (which Mestinon^® is commonly used) provides symptomatic treatment for patients and thus improves patient’s quality of life.

The Invida oncology portfolio aims to provide oncologists with innovative products for supportive care and treatment. We understand the negative impact of cancer on patients and caregivers, thus offering products which help patients manage their treatment regimen more effectively. 

Xclair™
Radiation dermatitis is a common side effect of radiation treatment. Radiation dermatitis is often unpleasant and painful which contribute to poor quality of life for patients. In some cases, radiation dermatitis may be so severe that interruption or cessation of radiation treatment is unavoidable.

Xclair™ contains key ingredients (Hyaluronic acid, Glycyrrhetinic acid, Vitis Vinifera, Shea Butter, Telmestine, Bisabolol in a hydro-lipidic base) that are designed and formulated specially for patients with radiation dermatitis. It is well supported with clinical evidences and have approved indication to manage and relieve itching, burning and pain experienced with radiation dermatitis. The barrier action of Xclair™ helps to maintain a moist skin environment, which is beneficial to the healing process. Xclair™ does not contain milk, animal derivatives or fragrance.

Patients are able to start applying Xclair™ few weeks before treatment to maintain optimum skin condition before radiation and continue to apply on the skin area three times daily (or as needed) during or after the radiation cycle by massaging gently into the skin. Xclair™ should not be applied less than four hours before radiation treatment.

Xclair™ will soon be available in Asia. Please consult your doctor for more information.

Mestinon® (pyridostigmine bromide) 
Mestinon® (pyridostigmine bromide) is an oral acetylcholinesterase inhibitor indicated for symptomatic relief in patients with Myasthenia Gravis (MG), a neuromuscular disease leading to fluctuating muscle weakness and fatigue. Mestinon® has been used for more than 50 years and continues to be the most widely used first-line treatment for generalized and ocular MG. Mestinon® is effective as long-term treatment of milder, especially ocular, myasthenia gravis through its fast acting, tolerable action.

In line with our strong foundation in Neurology, INVIDA set up the Specialist Interest Group of Myasthenia Gravis in Asia (SIGMA) in 2009. This special interest group brings together top neurologists from around the region to discuss diagnosis and treatment practices of Myasthenia Gravis. A publication entitled “Good Clinical Practice Points on the use of Acetylcholinesterase Inhibitors in Myasthenia Gravis: Recommendations from the Asian Regional Special Interest Group on Myasthenia Gravis” was published in Neurology Asia which provides recommendation on treatment for patients.

In an effort to create disease awareness of MG, SIGMA recently developed an information website to provide patients and physicians in Asia information about the disease www.myasthenia.asia

Sancuso^® Granisetron Transdermal System
Chemotherapy induced nausea and vomiting (CINV) is a common side effect of chemotherapy, which many people assume is unavoidable. However, with optimal treatment, patients need not have to experience nausea and vomiting unnecessarily. 

 Sancuso^™ is the first and only transdermal system used for CINV management. The active ingredient of Sancuso™, is delivered through the skin. Besides the ease and flexibility of administration, a single patch delivers 3.1mg of granisetron every 24 hours and can potentially prevent CINV for up to 5 consecutive days after chemotherapy, thus providing convenience and improves compliance in patients.

Sancuso™is current available in the Philippines. Please consult your doctor for more information.